A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults

NCT03572062

Last updated date
Study Location
Mater Hospital
South Brisbane, Queensland, 4101, Australia
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65-85 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.

2. Healthy adults who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.

3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests, and other study procedures.

4. Male and nonchildbearing-potential female adults aged 65 to 85 years at the time of enrollment (signing of the ICD).

5. Subjects must have received the primary vaccination (RSV vaccine or placebo) at Visit 1 and have signed and dated the ICD for participating in the revaccination stage (applies to Primary Study Cohort - Stage 2 subjects).

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
subjects who are Pfizer employees, including their family members, directly involved
in the conduct of the study.


2. Participation in other studies involving investigational product within 28 days prior
to study entry and/or during study participation.


3. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).


4. Previous vaccination with any licensed or investigational RSV vaccine before
enrollment into the study, or planned receipt throughout the study of nonstudy RSV
vaccine.


5. Vaccination with any influenza vaccine within 6 months (182 days) before
investigational product administration (applies to Primary Study Cohort - Stages 1 and
2).


6. History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the investigational product(s),
including natural rubber latex. In addition, a history of severe allergic reaction
(eg, anaphylaxis) to any substance, including documented allergy to egg proteins (egg
or egg products) or chicken proteins.


7. Subjects with known or suspected immunodeficiency, as determined by history and/or
laboratory/physical examination.


8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or
planned receipt throughout the study. If systemic corticosteroids have been
administered short term (<14 days) for treatment of an acute illness, subjects should
not be enrolled into the study until corticosteroid therapy has been discontinued for
at least 28 days before investigational product administration.Inhaled/nebulized,
intra-articular, intrabursal, or topical (epidural, skin or eyes) corticosteroids are
permitted.


9. Subject with a history of autoimmune disease or an active autoimmune disease requiring
therapeutic intervention including but not limited to: systemic or cutaneous lupus
erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré
syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura,
autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal
arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).


10. Receipt of blood/plasma products or immunoglobulin, from 60 days before
investigational product administration or planned receipt throughout the study.


11. Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.


12. Female subjects of childbearing potential or who are pregnant or breastfeeding;
fertile male subjects who are unwilling to use a highly effective method of
contraception for at least 28 days after the last dose of investigational product.


13. Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.


14. Planned donation of blood volumes of approximately 470 mL within 12 weeks after
Vaccination 1 (applies to subjects having additional blood drawn for cellular assays).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionA Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
  1. Los Angeles, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Los Angeles, California
  5. Los Angeles, California
  6. Caba,
  7. Caba,
  8. Turku,
  9. Auckland,
  10. Birmingham, Alabama
  11. Birmingham, Alabama
  12. Birmingham, Alabama
  13. Birmingham, Alabama
  14. Birmingham, Alabama
  15. Birmingham, Alabama
  16. Birmingham, Alabama
  17. Birmingham, Alabama
  18. Cullman, Alabama
  19. Cullman, Alabama
  20. Cullman, Alabama
  21. Mobile, Alabama
  22. Mobile, Alabama
  23. Mobile, Alabama
  24. Phoenix, Arizona
  25. Phoenix, Arizona
  26. Phoenix, Arizona
  27. Tucson, Arizona
  28. Tucson, Arizona
  29. Tucson, Arizona
  30. Tucson, Arizona
  31. Tucson, Arizona
  32. Jonesboro, Arkansas
  33. Jonesboro, Arkansas
  34. Jonesboro, Arkansas
  35. Jonesboro, Arkansas
  36. Chowchilla, California
  37. Huntington Park, California
  38. Huntington Park, California
  39. Huntington Park, California
  40. Lancaster, California
  41. Lancaster, California
  42. Loma Linda, California
  43. Loma Linda, California
  44. Loma Linda, California
  45. Loma Linda, California
  46. Loma Linda, California
  47. Long Beach, California
  48. Long Beach, California
  49. Long Beach, California
  50. Los Angeles, California
  51. Los Angeles, California
  52. Los Angeles, California
  53. Madera, California
  54. Madera, California
  55. Madera, California
  56. Madera, California
  57. Santa Monica, California
  58. Santa Monica, California
  59. Santa Monica, California
  60. Stanford, California
  61. Thousand Oaks, California
  62. Ventura, California
  63. Aurora, Colorado
  64. Aurora, Colorado
  65. Aurora, Colorado
  66. Aurora, Colorado
  67. Aurora, Colorado
  68. Aurora, Colorado
  69. Aurora, Colorado
  70. Aurora, Colorado
  71. Delta, Colorado
  72. Fruita, Colorado
  73. Grand Junction, Colorado
  74. Grand Junction, Colorado
  75. Grand Junction, Colorado
  76. Grand Junction, Colorado
  77. Grand Junction, Colorado
  78. Montrose, Colorado
  79. Washington, District of Columbia
  80. Washington, District of Columbia
  81. Washington, District of Columbia
  82. Loxahatchee Groves, Florida
  83. Miami, Florida
  84. North Miami Beach, Florida
  85. North Miami Beach, Florida
  86. Panama City, Florida
  87. Panama City, Florida
  88. Panama City, Florida
  89. Panama City, Florida
  90. Pembroke Pines, Florida
  91. Pembroke Pines, Florida
  92. Atlanta, Georgia
  93. Atlanta, Georgia
  94. Atlanta, Georgia
  95. Atlanta, Georgia
  96. Augusta, Georgia
  97. Augusta, Georgia
  98. Columbus, Georgia
  99. Columbus, Georgia
  100. Blackfoot, Idaho
  101. Blackfoot, Idaho
  102. Blackfoot, Idaho
  103. Idaho Falls, Idaho
  104. Idaho Falls, Idaho
  105. Nampa, Idaho
  106. Nampa, Idaho
  107. Nampa, Idaho
  108. Pocatello, Idaho
  109. Pocatello, Idaho
  110. Fort Wayne, Indiana
  111. Fort Wayne, Indiana
  112. Ames, Iowa
  113. Ames, Iowa
  114. Ames, Iowa
  115. Ames, Iowa
  116. Ankeny, Iowa
  117. West Des Moines, Iowa
  118. West Des Moines, Iowa
  119. El Dorado, Kansas
  120. Kansas City, Kansas
  121. Newton, Kansas
  122. Wichita, Kansas
  123. Wichita, Kansas
  124. Owensboro, Kentucky
  125. Owensboro, Kentucky
  126. Alexandria, Louisiana
  127. Alexandria, Louisiana
  128. Covington, Louisiana
  129. Gretna, Louisiana
  130. Lafayette, Louisiana
  131. Metairie, Louisiana
  132. New Orleans, Louisiana
  133. New Orleans, Louisiana
  134. New Orleans, Louisiana
  135. New Orleans, Louisiana
  136. New Orleans, Louisiana
  137. New Orleans, Louisiana
  138. New Orleans, Louisiana
  139. New Orleans, Louisiana
  140. Slidell, Louisiana
  141. Boston, Massachusetts
  142. Boston, Massachusetts
  143. Detroit, Michigan
  144. Detroit, Michigan
  145. Detroit, Michigan
  146. Southfield, Michigan
  147. Blaine, Minnesota
  148. Coon Rapids, Minnesota
  149. Coon Rapids, Minnesota
  150. Coon Rapids, Minnesota
  151. Fridley, Minnesota
  152. Maple Grove, Minnesota
  153. Minneapolis, Minnesota
  154. Minneapolis, Minnesota
  155. Minneapolis, Minnesota
  156. Gulfport, Mississippi
  157. Saint Louis, Missouri
  158. Saint Louis, Missouri
  159. Saint Louis, Missouri
  160. Saint Louis, Missouri
  161. Butte, Montana
  162. Great Falls, Montana
  163. Helena, Montana
  164. Kalispell, Montana
  165. Missoula, Montana
  166. Grand Island, Nebraska
  167. Hastings, Nebraska
  168. Lincoln, Nebraska
  169. Lincoln, Nebraska
  170. Lincoln, Nebraska
  171. Norfolk, Nebraska
  172. Las Vegas, Nevada
  173. Las Vegas, Nevada
  174. Las Vegas, Nevada
  175. Camden, New Jersey
  176. Camden, New Jersey
  177. Camden, New Jersey
  178. Cherry Hill, New Jersey
  179. New Brunswick, New Jersey
  180. Newark, New Jersey
  181. Newark, New Jersey
  182. Newark, New Jersey
  183. Newark, New Jersey
  184. Sewell, New Jersey
  185. Albuquerque, New Mexico
  186. Albuquerque, New Mexico
  187. East Setauket, New York
  188. East Setauket, New York
  189. East Setauket, New York
  190. Endwell, New York
  191. Flushing, New York
  192. Flushing, New York
  193. Fresh Meadows, New York
  194. Hollis, New York
  195. Jackson Heights, New York
  196. Johnson City, New York
  197. Mineola, New York
  198. Mineola, New York
  199. Mineola, New York
  200. Mineola, New York
  201. New Hyde Park, New York
  202. New York, New York
  203. New York, New York
  204. New York, New York
  205. New York, New York
  206. New York, New York
  207. New York, New York
  208. Rochester, New York
  209. Stony Brook, New York
  210. Durham, North Carolina
  211. Durham, North Carolina
  212. Durham, North Carolina
  213. Durham, North Carolina
  214. Pinehurst, North Carolina
  215. Pinehurst, North Carolina
  216. Raleigh, North Carolina
  217. Seven Lakes, North Carolina
  218. Southern Pines, North Carolina
  219. Southern Pines, North Carolina
  220. Dayton, Ohio
  221. Englewood, Ohio
  222. Yukon, Oklahoma
  223. Erie, Pennsylvania
  224. Erie, Pennsylvania
  225. Erie, Pennsylvania
  226. Erie, Pennsylvania
  227. Hershey, Pennsylvania
  228. Hershey, Pennsylvania
  229. Philadelphia, Pennsylvania
  230. Philadelphia, Pennsylvania
  231. West Reading, Pennsylvania
  232. West Reading, Pennsylvania
  233. West Reading, Pennsylvania
  234. Charleston, South Carolina
  235. Charleston, South Carolina
  236. Greenville, South Carolina
  237. Greenville, South Carolina
  238. Greenville, South Carolina
  239. Summerville, South Carolina
  240. Summerville, South Carolina
  241. Clarksville, Tennessee
  242. Knoxville, Tennessee
  243. Arlington, Texas
  244. Austin, Texas
  245. Beaumont, Texas
  246. Beaumont, Texas
  247. Beaumont, Texas
  248. Beaumont, Texas
  249. Burleson, Texas
  250. Dallas, Texas
  251. Dickinson, Texas
  252. Fort Worth, Texas
  253. Fort Worth, Texas
  254. Galveston, Texas
  255. Georgetown, Texas
  256. Georgetown, Texas
  257. Georgetown, Texas
  258. Georgetown, Texas
  259. Grapevine, Texas
  260. Houston, Texas
  261. Houston, Texas
  262. Houston, Texas
  263. Houston, Texas
  264. Houston, Texas
  265. Houston, Texas
  266. Houston, Texas
  267. Houston, Texas
  268. Houston, Texas
  269. Houston, Texas
  270. Lampasas, Texas
  271. Lampasas, Texas
  272. League City, Texas
  273. Longview, Texas
  274. Longview, Texas
  275. Longview, Texas
  276. Longview, Texas
  277. McAllen, Texas
  278. Plano, Texas
  279. San Antonio, Texas
  280. San Antonio, Texas
  281. Tomball, Texas
  282. Weatherford, Texas
  283. Salt Lake City, Utah
  284. Salt Lake City, Utah
  285. Salt Lake City, Utah
  286. Salt Lake City, Utah
  287. Salt Lake City, Utah
  288. Salt Lake City, Utah
  289. Salt Lake City, Utah
  290. Salt Lake City, Utah
  291. Norfolk, Virginia
  292. Norfolk, Virginia
  293. Richmond, Virginia
  294. Richmond, Virginia
  295. Richmond, Virginia
  296. Richmond, Virginia
  297. Richmond, Virginia
  298. Richmond, Virginia
  299. Richmond, Virginia
  300. Virginia Beach, Virginia
  301. Seattle, Washington
  302. Seattle, Washington
  303. Seattle, Washington
  304. Seattle, Washington
  305. Seattle, Washington
  306. Seattle, Washington
  307. Seattle, Washington
  308. Shoreline, Washington
  309. Tacoma, Washington
  310. Tacoma, Washington
  311. Tacoma, Washington
  312. Tacoma, Washington
  313. Tacoma, Washington
  314. Huntington, West Virginia
  315. Huntington, West Virginia
  316. Huntington, West Virginia
  317. Huntington, West Virginia
  318. Marshfield, Wisconsin
  319. Marshfield, Wisconsin
  320. San Miguel de Tucuman, Tucuman
  321. San Miguel de Tucuman, Tucuman
  322. Buenos Aires,
  323. North Adelaide, South Australia
  324. Clayton, Victoria
  325. Clayton, Victoria
  326. Geelong, Victoria
  327. Sorocaba, SP
  328. Montreal, Quebec
  329. Quebec,
  330. Osorno, Región DE LOS Lagos
  331. Santiago, Región Metropolitana
  332. Santiago, Región Metropolitana
  333. Santiago, Región Metropolitana
  334. Santiago, Región Metropolitana
  335. Santiago, Región Metropolitana
  336. Santiago, Región Metropolitana
  337. Santiago, Región Metropolitana
  338. Aarhus N,
  339. Hillerod,
  340. Hvidovre,
  341. Odense C,
  342. Helsinki,
  343. Kokkola,
  344. Oulu,
  345. Pori,
  346. Seinajoki,
  347. Tampere,
  348. Turku,
  349. Fujisawa, Kanagawa
  350. Hoofddorp,
  351. Utrecht,
  352. Utrecht,
  353. Christchurch,
  354. Christchurch,
  355. Wellington,
  356. Bloemfontein, FREE State
  357. Hillbrow, Johannesburg, Gauteng
  358. Johannesburg, Gauteng
  359. Soshanguve, Gauteng
  360. Soweto, Gauteng
  361. Khayelitsha, Western CAPE
  362. Parow Valley, Western CAPE
  363. Cape Town,
  364. Worcester,
  365. Santiago de Compostela, A Coruna
  366. Antequera, Malaga
  367. Madrid,
  368. Madrid,
  369. Mostoles,
  370. Valencia,
  371. Hsinchu City,
  372. Kaohsiung,
  373. Taipei City,
  374. Taipei,
  375. Taoyuan,
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
  1. South Brisbane, Queensland
  2. South Brisbane, Queensland
  3. Geelong, Victoria
  4. Fountain Hills, Arizona
  5. San Diego, California
  6. Coral Gables, Florida
  7. South Miami, Florida
  8. Peoria, Illinois
  9. Fremont, Nebraska
  10. Omaha, Nebraska
  11. Omaha, Nebraska
  12. Rochester, New York
  13. Rochester, New York
  14. South Jordan, Utah
  15. Adamstown, New South Wales
  16. Maroubra, New South Wales
  17. Merewether, New South Wales
  18. Sydney, New South Wales
  19. Sydney, New South Wales
  20. Westmead, New South Wales
  21. Westmead, New South Wales
  22. Sherwood, Queensland
  23. Box Hill, Victoria
  24. Box Hill, Victoria
  25. Camberwell, Victoria
  26. Camberwell, Victoria
  27. Clayton, Victoria
  28. Clayton, Victoria
  29. Geelong, Victoria
  30. Ivanhoe, Victoria
  31. Murdoch, Western Australia
  32. Murdoch, Western Australia
  33. Nedlands, Western Australia
  34. Nedlands, Western Australia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
  1. Santiago, Region Metropolitana
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Cullman, Alabama
  6. Cullman, Alabama
  7. Cullman, Alabama
  8. Phoenix, Arizona
  9. Tucson, Arizona
  10. Tucson, Arizona
  11. Chowchilla, California
  12. Huntington Park, California
  13. Huntington Park, California
  14. Los Angeles, California
  15. Los Angeles, California
  16. Madera, California
  17. Madera, California
  18. Madera, California
  19. Madera, California
  20. Aurora, Colorado
  21. Aurora, Colorado
  22. Aurora, Colorado
  23. Aurora, Colorado
  24. Aurora, Colorado
  25. Aurora, Colorado
  26. Aurora, Colorado
  27. Atlanta, Georgia
  28. Atlanta, Georgia
  29. Blackfoot, Idaho
  30. Blackfoot, Idaho
  31. Blackfoot, Idaho
  32. Idaho Falls, Idaho
  33. Idaho Falls, Idaho
  34. Idaho Falls, Idaho
  35. Idaho Falls, Idaho
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Nampa, Idaho
  39. Nampa, Idaho
  40. Nampa, Idaho
  41. Nampa, Idaho
  42. Pocatello, Idaho
  43. Pocatello, Idaho
  44. Ankeny, Iowa
  45. West Des Moines, Iowa
  46. West Des Moines, Iowa
  47. El Dorado, Kansas
  48. Hutchinson, Kansas
  49. Alexandria, Louisiana
  50. Gretna, Louisiana
  51. Marrero, Louisiana
  52. Metairie, Louisiana
  53. Metairie, Louisiana
  54. New Orleans, Louisiana
  55. New Orleans, Louisiana
  56. Boston, Massachusetts
  57. Blaine, Minnesota
  58. Coon Rapids, Minnesota
  59. Coon Rapids, Minnesota
  60. Coon Rapids, Minnesota
  61. Coon Rapids, Minnesota
  62. Minneapolis, Minnesota
  63. Biloxi, Mississippi
  64. Gulfport, Mississippi
  65. Gulfport, Mississippi
  66. Gulfport, Mississippi
  67. Saint Louis, Missouri
  68. Saint Louis, Missouri
  69. Saint Louis, Missouri
  70. Missoula, Montana
  71. Missoula, Montana
  72. Lincoln, Nebraska
  73. Lincoln, Nebraska
  74. Lincoln, Nebraska
  75. Norfolk, Nebraska
  76. Henderson, Nevada
  77. Las Vegas, Nevada
  78. Albuquerque, New Mexico
  79. Albuquerque, New Mexico
  80. Albuquerque, New Mexico
  81. Binghamton, New York
  82. Endwell, New York
  83. Hempstead, New York
  84. Johnson City, New York
  85. Johnson City, New York
  86. Mineola, New York
  87. Mineola, New York
  88. Mineola, New York
  89. Mineola, New York
  90. Rochester, New York
  91. Rochester, New York
  92. Durham, North Carolina
  93. Durham, North Carolina
  94. Durham, North Carolina
  95. Durham, North Carolina
  96. Dayton, Ohio
  97. Dayton, Ohio
  98. Englewood, Ohio
  99. Kettering, Ohio
  100. Summerville, South Carolina
  101. Summerville, South Carolina
  102. Summerville, South Carolina
  103. Beaumont, Texas
  104. Beaumont, Texas
  105. Beaumont, Texas
  106. Beaumont, Texas
  107. Fort Worth, Texas
  108. Fort Worth, Texas
  109. Galveston, Texas
  110. Georgetown, Texas
  111. Georgetown, Texas
  112. Georgetown, Texas
  113. Georgetown, Texas
  114. Houston, Texas
  115. Houston, Texas
  116. Houston, Texas
  117. Houston, Texas
  118. Houston, Texas
  119. Houston, Texas
  120. Lampasas, Texas
  121. Lampasas, Texas
  122. Longview, Texas
  123. Longview, Texas
  124. Longview, Texas
  125. McAllen, Texas
  126. Pharr, Texas
  127. Plano, Texas
  128. Plano, Texas
  129. Round Rock, Texas
  130. Tomball, Texas
  131. Murray, Utah
  132. Salt Lake City, Utah
  133. Salt Lake City, Utah
  134. Salt Lake City, Utah
  135. Salt Lake City, Utah
  136. Salt Lake City, Utah
  137. Salt Lake City, Utah
  138. Richmond, Virginia
  139. Richmond, Virginia
  140. Huntington, West Virginia
  141. Huntington, West Virginia
  142. Huntington, West Virginia
  143. Huntington, West Virginia
  144. San Miguel de Tucuman, Tucuman
  145. San Miguel de Tucuman, Tucuman
  146. Cordoba,
  147. Salta,
  148. San Miguel de Tucuman,
  149. Santiago, Region Metropolitana
  150. Osorno, Región DE LOS Lagos
  151. Santiago, Región Metropolitana
  152. Santiago, Región Metropolitana
  153. Santiago, Región Metropolitana
  154. Santiago, Región Metropolitana
  155. Santiago, RM
  156. Soweto, Gauteng
  157. Soweto, Gauteng
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
NCT04071158
  1. Stockbridge, Georgia
  2. Honolulu, Hawaii
  3. Wichita, Kansas
  4. Saint Louis, Missouri
  5. Omaha, Nebraska
  6. Oklahoma City, Oklahoma
  7. Warwick, Rhode Island
  8. Dakota Dunes, South Dakota
  9. Austin, Texas
  10. Fort Worth, Texas
  11. Houston, Texas
  12. San Antonio, Texas
  13. San Antonio, Texas
  14. Tomball, Texas
  15. Tomball, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. South Jordan, Utah
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
Official Title  ICMJE A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF AN ADJUVANTED RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY OLDER ADULTS
Brief Summary

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with seasonal inactivated influenza vaccine (SIIV) and may evaluate a second dose of RSV vaccine administered12 months after the initial dose.

In addition the study will evaluate a 2-dose regimen administered 2 months apart to 62 subjects.

Detailed Description

The study will evaluate the safety, tolerability, and immunogenicity of up to 7 different RSV vaccine candidates, some with adjuvant, when administered concomitantly with SIIV. Healthy male and female subjects between 65 to 85 years of age will be enrolled. Subjects will receive 2 intramuscular injections to assess the concomitant administration of SIIV when given to subjects receiving one of the 3 RSV vaccine dose-level candidates formulated with or without an adjuvant.

If interim support implementation of revaccination, invited, consenting subjects will be revaccinated with the same dose and formulation of the RSV vaccine or placebo received at Visit 1, concomitantly with SIIV. The safety, tolerability, and immunogenicity of the second dose will be evaluated through 12 months after revaccination.

62 subjects will be randomized 1:1 to receive a dose of high dose adjuvanted RSV vaccine or placebo followed by a second dose 2 months later. Safety, tolerability, and immunogenicity will be evaluated. The subjects will be enrolled before the influenza season. There will be no concomitant SIIV administration.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Parallel
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
Observer blind
Primary Purpose: Prevention
Condition  ICMJE Respiratory Tract Infection
Intervention  ICMJE
  • Biological: Formulation A
    RSV vaccine
  • Biological: Formulation B
    Adjuvanted RSV vaccine
  • Biological: Formulation C
    RSV vaccine
  • Biological: Placebo
    Placebo
Study Arms  ICMJE
  • Experimental: Arm 1
    Low dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Arm 2
    Low dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Arm 3
    Mid dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Arm 4
    Mid dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Arm 5
    High dose formulation A and SIIV
    Intervention: Biological: Formulation A
  • Experimental: Arm 6
    High dose formulation B and SIIV
    Intervention: Biological: Formulation B
  • Experimental: Arm 7
    High dose formulation C and SIIV
    Intervention: Biological: Formulation C
  • Placebo Comparator: Arm 8
    Placebo and SIIV
    Intervention: Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 10, 2020)
317
Original Estimated Enrollment  ICMJE
 (submitted: June 18, 2018)
474
Actual Study Completion Date  ICMJE August 20, 2020
Actual Primary Completion Date June 23, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.
  2. Healthy adults who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests, and other study procedures.
  4. Male and nonchildbearing-potential female adults aged 65 to 85 years at the time of enrollment (signing of the ICD).
  5. Subjects must have received the primary vaccination (RSV vaccine or placebo) at Visit 1 and have signed and dated the ICD for participating in the revaccination stage (applies to Primary Study Cohort - Stage 2 subjects).

Exclusion Criteria:

  1. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  2. Participation in other studies involving investigational product within 28 days prior to study entry and/or during study participation.
  3. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
  4. Previous vaccination with any licensed or investigational RSV vaccine before enrollment into the study, or planned receipt throughout the study of nonstudy RSV vaccine.
  5. Vaccination with any influenza vaccine within 6 months (182 days) before investigational product administration (applies to Primary Study Cohort - Stages 1 and 2).
  6. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product(s), including natural rubber latex. In addition, a history of severe allergic reaction (eg, anaphylaxis) to any substance, including documented allergy to egg proteins (egg or egg products) or chicken proteins.
  7. Subjects with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  8. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration.Inhaled/nebulized, intra-articular, intrabursal, or topical (epidural, skin or eyes) corticosteroids are permitted.
  9. Subject with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome,multiple sclerosis, Sjögren syndrome, idiopathic thrombocytopenic purpura, autoimmune glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
  10. Receipt of blood/plasma products or immunoglobulin, from 60 days before investigational product administration or planned receipt throughout the study.
  11. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  12. Female subjects of childbearing potential or who are pregnant or breastfeeding; fertile male subjects who are unwilling to use a highly effective method of contraception for at least 28 days after the last dose of investigational product.
  13. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  14. Planned donation of blood volumes of approximately 470 mL within 12 weeks after Vaccination 1 (applies to subjects having additional blood drawn for cellular assays).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 65 Years to 85 Years   (Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03572062
Other Study ID Numbers  ICMJE C3671002
RSV ADJUVANT ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date September 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP